Table II.

Efficacy and toxicities in first-line FOLFOX4.

First-line result, % (95% CI)
Objective response rate	31.4 (16.1–46.7%)
Disease control rate	62.8 (46.8–78.8%)
Median PFS in months	6.0 (5.4–6.5)
Range	2.8–10.5
Reasons for discontinuing treatment, (n, %)
Disease progression	25 (71.4)
Neurotoxicity	3 (8.6)
Allergy	7 (20.0)
Hematological toxicity (grade ≥3), (n, %)
Leukopenia	4 (11.4)
Neutropenia	20 (57.1)
Anemia	1 (2.8)
Febrile neutropenia	1 (2.8)

CI, confidence interval; PFS, progression-free survival.